GYRE THERAPEUTICS, INC. 8-K

What Happened

• Gyre Therapeutics, Inc. announced in an 8-K that on July 10, 2026 its Board appointed Yue Xiong, Ph.D. as a Class I director, Maxwell Kirkby as a Class II director, and Claire Weston, Ph.D. as a Class III director, all effective August 1, 2026. Mr. Kirkby was named to the Compensation Committee and Dr. Weston to the Audit Committee.

Key Details

• Mr. Kirkby and Dr. Weston will each receive an initial grant of stock options to purchase 40,000 shares of common stock, vesting in equal monthly installments over three years (80,000 shares total potential).
• Mr. Kirkby and Dr. Weston will receive cash compensation under the company’s non-employee director compensation policy (as described in the Proxy Statement filed April 27, 2026).
• Dr. Xiong, who is already the company’s Chief Scientific Officer, previously entered the company’s indemnification agreement and will receive no additional compensation for his Board service.
• The company furnished a press release about the appointments as Exhibit 99.1 to the 8-K (filed July 16, 2026).

Why It Matters

• These appointments change the composition of Gyre’s Board and place new members on key committees (Audit and Compensation), which affects governance and oversight. The option grants to two new directors create potential dilution of up to 80,000 shares and represent a future stock‑based compensation commitment. Investors should note the effective date (Aug 1, 2026) and that these are standard governance and compensation actions disclosed under Item 5.02 of the Form 8-K.